

Hertfordshire and West Essex Integrated Care System



Evidence Based Intervention

Dysthyroid Eye Disease

July 2022 v1.0

Document Owner:	Dr Rachel Joyce – Medical Director	
Document Author(s):	Clinical Policies Group	
Version:	v1.0	
Approved By:	Commissioning Committee	
Date of Approval:	1st July 2022	
Date of Review:	1st July 2024	
	If the review date has exceeded, the published policy remains valid	

Dysthyroid Eye Disease July 2022 v1.0 Hertfordshire and West Essex Integrated Care Board

Page 1 of 3

Policy:

This policy has been produced on behalf of local ICBs and covers ICB funding of thyroid eye disease, clarifying the responsibilities of ICBs and NHSE in the commissioning and funding of thyroid eye disease. The guidance does not cover NHSE funding but clarifies where their responsibilities lie.

Treatment of thyroid eye disease (TED) is only funded by ICB's in cases of mild disease (see classification below). For moderate or severe disease NHS England is the responsible commissioner. The treatment of mild disease is primarily medical, not surgical, therefore it is not anticipated that any surgery for thyroid eye disease would be routinely funded by local ICB's.

Spectacle lenses including specialist lenses are also an NHS England responsibility.

Funding criteria:

Any requests for ICB funding of surgery would be exceptional and would only be considered as an individual funding request (IFR). See appendix A for OPCS codes.

The ICB funding responsibilities are for mild disease, with NHSE the commissioner for moderate or severe disease. Disease severity is assessed using the EUGOGO criteria, shown below.(1)

Sign/symptom	Mild disease	Moderate/severe disease
Lid retraction	<2 mm	≥2 mm
Soft tissue involvement	Mild	Moderate or severe
Exophthalmos	<3 mm	≥3 mm
Diplopia	None or transient ^a	Inconstant ^b or constant ^c
Corneal involvement*	None or mild	Moderate or severe

a Transient diplopia: in primary position when tired or first awakening

b Inconstant diplopia: at extremes of gaze

c Constant diplopia: continuous in primary position or when reading

*Punctate keratopathy responsive to topical lubricants within 1 week would be classified mild. All other corneal involvement e.g. non-responsive punctate keratopathy, ulcer or perforation is considered moderate/severe.

Clinical management

Management appropriate for mild disease:

Management of mild disease is mostly self-management optimisation of the patient's thyroid status, eg:

Smoking cessation

Dysthyroid Eye Disease July 2022 v1.0 Hertfordshire and West Essex Integrated Care Board Page **2** of **5**

- Correction of thyroid function
- Artificial tears (obtained over the counter from community pharmacies)
- Prism lenses (NHSE responsibility)
- Self-help groups

Management appropriate for moderate to severe disease – (NB NHS England is responsible for commissioning)

- IV steroids
- Orbital irradiation
- Orbital decompression
- Muscle surgery
- Eyelid surgery

References

1. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008 Mar 1;158(3):273–85.

Appendix A - OPCS Codes

- C06.3 Decompression of orbit
- C13.1 Blepharoplasty of both eyelids
- C13.2 Blepharoplasty of upper eyelid
- C13.3 Blepharoplasty of lower eyelid
- C16.1 Central tarsorrhaphy
- C16.2 Lateral tarsorrhaphy
- C16.3 Medial tarsorrhaphy
- C16.4 Tarsorrhaphy NEC
- C16.5 Revision of tarsorrhaphy
- C18.5 Tarsomullerectomy
- C31.1 Recession of medial rectus muscle and resection of lateral rectus muscle of eye
- C31.2 Bilateral recession of medial recti muscles of eyes
- C31.3 Bilateral resection of medial recti muscles of eyes
- C31.4 Bilateral recession of lateral recti muscles of eyes
- C31.5 Bilateral resection of lateral recti muscles of eyes

C31.6 Recession of lateral rectus muscle and resection of medial rectus muscle of eye C31.8 Other specified combined operations on muscles of eye C31.9 Unspecified combined operations on muscles of eye C32.1 Recession of medial rectus muscle of eye NEC C32.2 Recession of lateral rectus muscle of eye NEC C32.3 Recession of superior rectus muscle of eye C32.4 Recession of inferior rectus muscle of eye C32.5 Recession of superior oblique muscle of eye C32.6 Recession of inferior oblique muscle of eye C32.7 Recession of combinations of muscles of eye C32.8 Other specified recession of muscle of eye C32.9 Unspecified recession of muscle of eye C33.1 Resection of medial rectus muscle of eye NEC C33.2 Resection of lateral rectus muscle of eye NEC C33.3 Resection of superior rectus muscle of eye C33.4 Resection of inferior rectus muscle of eye C33.5 Resection of superior obligue muscle of eye C33.6 Resection of inferior oblique muscle of eye C33.7 Resection of combinations of muscles of eye C33.8 Other specified resection of muscle of eye C33.9 Unspecified resection of muscle of eye C34.1 Tenotomy of medial rectus muscle of eye C34.2 Tenotomy of lateral rectus muscle of eye C34.3 Tenotomy of superior rectus muscle of eye C34.4 Tenotomy of inferior rectus muscle of eye C34.5 Tenotomy of superior oblique muscle of eye C34.6 Tenotomy of inferior oblique muscle of eye C34.7 Tenotomy of combinations of muscles of eye

Dysthyroid Eye Disease July 2022 v1.0 Hertfordshire and West Essex Integrated Care Board Page 4 of 5

- C34.8 Other specified partial division of tendon of muscle of eye
- C34.9 Unspecified partial division of tendon of muscle of eye
- C35.1 Transposition of muscle of eye NEC
- C35.2 Lengthening of muscle of eye by muscle slide
- C35.3 Insertion of adjustable suture into muscle of eye
- C35.8 Other specified other adjustment to muscle of eye
- C35.9 Unspecified other adjustment to muscle of eye
- C37.2 Freeing of adhesions of muscle of eye
- C37.4 Repair of muscle of eye NEC
- C37.8 Other specified other operations on muscle of eye
- C37.9 Unspecified other operations on muscle of eye
- X65.8 Other specified radiotherapy deliver

Change History:

Version	Date	Reviewer(s)	Revision Description

DOCUMENT CONTROL

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the website.

Do you really need to print this document?

Please consider the environment before you print this document and where copies should be printed double-sided. Please also consider setting the Page Range in the Print properties, when relevant to do so, to avoid printing the policy in its entirety.

Dysthyroid Eye Disease July 2022 v1.0 Hertfordshire and West Essex Integrated Care Board Page 5 of 5